Journal of Clinical Oncology (JCO) Podcast

More adjuvant chemotherapy is not always better for early breast cancer patients - Discussion and consequence for clinical practice.

The podcast reviews the evolution of staging and treatment of Hodgkin lymphoma, reducing the toxicities and torture while maintaining a high level of cure.

In this podcast, Attar and colleagues explore whether patients aged 60-75 who enter remission with bortezomib added to standard anthracycline plus cytarabine chemotherapy during induction can be safely treated with intermediate dose cytarabine along with dose escalating bortezomib during consolidation. This regimen was tolerated at the highest dose of bortezomib tested, 1.3 mg/m2, and further rand...

This podcast will review a JCO article showing that the use of breast brachytherapy as a method of delivering partial breast radiation after breast conserving surgery was associated with higher rates of complications than the conventional approach of whole breast radiation.

This Podcast provides observations and commentary about referral practices of oncologists to specialized palliative care.

This podcast characterizes the clinical utility of the screening tests recommended by the Children's Oncology Group in the care of long-term survivors.

Publication of a large collaborative group trial appears to definitively demonstrate the safety of sentinel lymph node biopsy as replacement for inguinal-femoral lymphadenectomy, or does it?

In this podcast, results of a randomized phase III clinical trial evaluating the use of Rituximab maintenance therapy following autologous stem cell transplantation in patients with relapsed diffuse large B cell lymphoma are summarized. The results demonstrate that Rituximab maintenance therapy does not result in improved event free or overall survival in this patient population.

Melissa Cousino and colleagues found that few parents understand the scientific purpose of phase I pediatric clinical trials.

The prognostic importance of ALK-protein expression was established over a decade ago. More recent studies emphasize that age is also an important driving force and in patients

Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.

This podcast summarizes and places in clinical context two studies describing straightforward immunohistochemical methods to risk-stratify diffuse large B-cell lymphoma.

Cognitive impairment occurs in a subset of breast cancer survivors after chemotherapy but the incidence remains unknown.

This podcast discusses the manuscript by Tejpar et al in which patients whose colorectal tumors harbor a specific KRAS mutation, G13D, appear to have benefit in two clinical trials with regard to tumor response and progression-free survival with cetuximab treatment.

Although historically toxicity was often thought to be a biomarker of efficacy, often it appears to be a marker of dose intensity and individual susceptibility as is the case in this retrospective study of taxane induced peripheral neuropathy and breast cancer outcome.

In this podcast, Dr. Hudis reviews the use of a novel nomogram to predict the benefits of postoperative adjuvant radiation therapy for older women with early stage breast cancer. This discussion highlights the information from prospective randomized trials, their limitations, and the potential for a nomogram to guide clinicians facing patients who might not have qualified for the earlier studies.

As oncologists treat an increasing number of older patients with colon cancer, and as treatment options improve for older patients, oncologists should work with geriatricians to make the best treatment decisions.

This podcast will provide a critical evaluation of the combination of bortezomib, thalidomide, and dexamethasone in relapsed multiple myeloma

This Podcast reviews and comments on the use of the National Comprehensive Cancer Network (NCCN) Breast Cancer Outcome Database to demonstrate the actual rollout of the use of gene expression profile (GEP) testing for women with hormone receptor positive, node negative breast cancer and the accompanying changes in breast cancer chemotherapy utilization

This Podcast reviews the design and results of the present study by Kennecke et al. and provides perspective regarding the clinical significance of these findings.

This podcast reviews the rationale behind evaluation of metformin as a potential anti-cancer agent in breast cancer and describes the findings of a recent window of opportunity trial looking at the impact of metformin upon proliferative indices in women with early breast cancer.

This podcast reviews the results of the FACT trial in the context of other ongoing and proposed studies of endocrine therapy combinations.

This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well.

In this study, the implications of long term follow up of the German Rectal Study on clinical practice and future trial design will be discussed.

Carboplatin-Gemcitabine-Bevacizumab represents an additional regimen to consider for management of recurrent platinum sensitive epithelial ovarian cancer, although it raises several questions regarding the role of bevacizumab in this disease setting.